GlassScriptPhysician profile
Bhumit P Patel
NPI 1144457722
$485.89
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $123.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $82.88 | 2019 | |
| Astellas Pharma US INC | $64.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $57.09 | 2019-2020 | |
| Novo Nordisk INC | $55.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.41 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.97 | 2019 | |
| Amgen INC. | $29.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.90 | 2019 | |
| Supernus Pharmaceuticals, INC. | $25.15 | 2020 | |
| Mylan Specialty L.P. | $21.44 | 2020 | |
| Radius Health, INC. | $18.60 | 2019 | |
| Shire North American Group INC | $12.84 | 2019 | |
| Allergan, INC. | $12.13 | 2020 | |
| Merck Sharp & Dohme LLC | $10.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhumit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.